Friday, June 16, 2023

mRNA vaccines fast-tracked for Australian agriculture

After the spectacular failure of mRNA vaccines in human trials, the agricultural industry is pushing ahead with mRNA vaccines for livestock engaged in the food industry.

Whispers of stock ‘dying suddenly’ will no doubt become a complaint of farmers in the future, summarily ignored by government in the same way officials refuse to listen to serious concerns about dam-building restrictions, price hikes on Ag products, ridiculous fees and charges, incomprehensible red and green tape, biosecurity regulations that do nothing, and – fresh out of Western Australia – expensive negotiations with Indigenous groups who have never set foot on the land they claim to ‘own’.

In one example that mRNA is on its way Down Under, on May 2, 2023, Meat and Livestock Australia (MLA) announced funding for a project to ‘test mRNA vaccines that can be rapidly mass-produced in Australia in the event of a lumpy skin disease or other exotic disease outbreak’.

The Manager for Animal Wellbeing, released a statement saying:

‘This project will develop a mRNA vaccine pipeline initially for LSD, but potentially for other emergency diseases. This will enable capacity for rapid mass production of a vaccine for LSD in the event of an outbreak. No LSD vaccines are registered for use in Australia yet. While some vaccines exist overseas, the path to registration in Australia for traditionally-produced [vaccines] is longer than that of an mRNA vaccine.’

Why are traditional vaccines, which have safety records that outstrip mRNA vaccines, subject to longer approval periods than mRNA vaccines? That sounds like a significant structural failure within Australia’s health body that, instead of being fixed, has the potential to be exploited by manufacturers looking to cash in on mRNA.

mRNA vaccines are quick to produce and ‘nimble’, which is why pharmaceutical companies like them – but that doesn’t mean that they are safe, effective, or suitable for consumers whether those are humans or livestock.

A 2022 article in PubMed Central notes: ‘Recently, the successful application of mRNA vaccines against Covid has further validated the platform and opened the floodgates to mRNA vaccine’s potential in infectious disease prevention, especially in the veterinary field.’

No doubt this is why we keep hearing bleatings of ‘emergency’ and ‘outbreak’ in the same breath as mRNA, as if to remind us of the mantra used during the Covid era to embark on what the former Health Minister referred to as the ‘largest clinical trial – the largest global vaccine trial ever’. Look how that turned out.

The fall-out of Covid mRNA vaccines is likely to continue for the best part of a century as a percentage of vaccinated individuals ‘die suddenly’ or suffer from long-term debilitating illnesses. These are quickly becoming a burden for the health industry and state finances after vaccine manufacturers hand-waved responsibility because it was an ‘emergency’. Most nations are setting up compensation pools of cash to cope with the growing list of individuals who claim to have been harmed.

Another excuse used to feather the nest of mRNA vaccines is that they are thought to provide the solution for influenza-style viruses which traditional vaccines have proven ineffective against. Everyone wants to see an effective vaccine against respiratory viruses, but it’s almost as if the doe-eyed vaccine industry has put on a blindfold for the last three years. mRNA Covid vaccines did next to nothing to combat or control the influenza-style Covid and do not, based on what we have seen, offer any advantage to traditional vaccines for this problem beyond the feel-good marketing headlines. There is a strong argument that for the majority of the population, they did more harm than good.

Instead of suspending all mRNA vaccines until we understand what went wrong, they are being given priority treatment by regulators and championed by manufacturers who love the competitive edge of speed their production offers. Governments, particularly the (broke?) Victorian state government, are funnelling tens of millions into mRNA development to keep capitalising on the political popularity they enjoyed during the Covid era.

MLA note that mRNA vaccines should be ready for use within two years and while everyone is busy stressing that this will be a ‘voluntary’ option for the farming community, vaccines inside the agricultural industry rarely are if a producer wishes to sell their product into domestic and international markets. If we go down the mRNA vaccine production line, it is extremely likely that Australians will be eating mRNA-vaccinated livestock within a couple of years with very little understanding of what this will mean health-wise.

Anyone who criticises mRNA vaccines or their potential future within the agricultural industry are paraded through the press as ‘conspiracy theorists’ with publications quick to send out the fact-checkers to insist that it’s pure fear-mongering to suggest fragments of these vaccines will end up in the food chain.

Except, it was a ‘conspiracy theory’ to suggest that the human body would continue making Covid mRNA vaccines long after the injection, or to raise concerns that it would leave the site of the injection. Not only did the fears described as ‘conspiracy’ prove to be true, the behaviour and side effects of Covid mRNA vaccines are reaching well beyond what anyone predicted.

How sure are we that in the rush to saturate the market with mRNA vaccines, that proper long-term testing will be conducted, particularly when it comes to lingering in meat and milk? Will it impact high-risk activities such as calving, given there is a strong suspicion that Covid vaccines are responsible for a spike in human miscarriages?

Keep in mind that we are still being told Covid vaccines are ‘safe and effective’. The Australian government, sitting on a pile of unwanted vaccines, is spending public money on marketing campaigns, encouraging Australians to go and get their booster shots at the same time other countries have removed Covid vaccines.

At least some States in the US are taking note, rushing to pass legislation to ban the use of mRNA vaccines for animals involved in the food industry whose meat or milk is produced for human consumption. Idaho is one example where it will be a misdemeanour to use mRNA vaccines – and that includes the Covid vaccines.

Australians need to be aware that mRNA vaccines are coming for the agricultural industry and they will likely be compulsory. America is having a serious conversation about whether this should be allowed, and Australia needs to do the same thing. It is perfectly reasonable to require extensive long-term safety data before we revolutionise agriculture.

This conversation will not happen on its own. Australia’s agricultural elite resemble a body of yes-men nodding furiously toward mRNA. Family farmers – disempowered, constrained, and demoralised – have no voice in this matter. Their wishes will be bulldozed by a small collection of billion-dollar farming entities, several of which are foreign-owned.

If Australians care about what they eat, it’s time to start making a racket.


Vaccine advisory group to meet, including vaccine critics

Current vaccines of little use

TrialSite has reported that this week, the Food and Drug Administration (FDA) Vaccines and Biological Products Advisory Committee (VRBPAC), a group of independent experts in the fields of virology and vaccinology, will meet tomorrow, Thursday June 15 from 8:30AM to 5:00PM ET, accessible via YouTube.

Among other presenters and speakers will be David Wiseman, Ph.D., a frequent TrialSite contributor and critique as to how government agencies such as the FDA have conducted its affairs during the pandemic. TrialSite has reported how both the World Health Organization (WHO) and the European Medicines Agency (EMA) and the European Centers for Disease Prevention and Control (ECDC) have made the call to accelerate the move away from the current COVID-19 vaccine formulations to more relevant Omicron strains such as those associated with XBB lineages.

TrialSite wrote and warned frequently during the early parts of the mass countermeasure roll out that it would be difficult to impossible to control SARS-CoV-2 with vaccines. A dynamic, mutating RNA virus, the pathogen drastically changed over the last couple years, emerging as not only more transmissible but also less severe. The pathogen increasingly evaded the defensive powers of the COVID-19 vaccines.

The FDA’s briefing artifacts point to a comparable direction for the American vaccine regulator. TrialSite reviewed the artifacts, finding that Pfizer, Moderna and Novavax need to advance formulations, becoming monovalent again, targeting the Omicron XBB sublineages with an emphasis on XBB.1.5, XBB.1.6 or XBB.2.3. The FDA now embraces a process comparable to how the specific annual influenza vaccine is selected.

The current COVID-19 vaccine in use in America, the bivalent booster (index strain plus Omicron BA.4/BA.5), has emerged as the only vaccine product recommended by the FDA. But there is just one problem: The strains that this vaccine targets are basically extinct. The quality of this product as measured by durability and breadth of effectiveness is questionable---at least this is the case according to TrialSite. Also as TrialSite’s founder recently argues for in an opinion piece, the government should invest in more detailed safety reviews.

So, expected at tomorrow’s meeting is that a strain will be selected, and then the pharmaceutical companies of Pfizer-BioNTech, Moderna and Novavax will be expected to update their platforms with the targeted updated strains. Importantly, as is the case with WHO, EMA and CDC, the pharmaceutical vaccine makers will not have to revalidate their platforms. This means that human clinical trials data will likely not be required assuming a sufficient collection of prespecified data meeting key targets are provided by the vaccine makers before authorization by the agency. However, this process has detractors, such as Dr. David Wiseman, who argues changes to formulation have included material modifications to the vaccines necessitating validation—meaning extensive clinical trials to verify efficacy and safety.

The current bivalent BA.4/BA.5 vaccine now streamlined as the only option in America based on a handful of studies affords only nominal to slightly improved neutralizing antibody protection against current predominant SARS-CoV-2 Omicron strains such as XBB and XBB.1 than compared to three doses of the original monovalent jab.

Moreover, the bivalent jabs met significant hesitance among the American healthcare market, COVID-19 or not. Americans were increasingly hesitant due to a confluence of factors including concerns about vaccine quality and safety. Under 20% of the eligible population opted to even receive the jab.

By February of 2023, the CDC reported that the XBB 1.5, an Omicron lineage, emerged as the predominant SARS-CoV-2 pathogen in circulation. First detected in October 2022, by May 2023, the University of Nebraska reported XBB.1.5 emerged with 53.8% of all cases, followed by XBB.1.16 with 15.1% of cases, and XBB.1.8.1 with 11.8 of cases. According to Dr. Mark Rupp, “The original omicron variant is gone now.”

The FDA has noted in the past that “intrinsic viral factors” such as rate of mutation and recombination potential suggest greater transmissibility and adaptation to the human host while host immune response and a confluence of other forces may contribute to selection of variants. An outspoken critic, Belgium vaccine specialist Geert vanden Bossche has gone on the record that it was a mistake to conduct a mass vaccination in the middle of a pandemic. While the conventional wisdom of medical and scientific establishments, often unduly influenced by industry, points to the vaccines saving millions of lives.




No comments: